SG Americas Securities LLC Decreases Stake in Amphastar Pharmaceuticals, Inc. $AMPH

SG Americas Securities LLC trimmed its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 64.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,806 shares of the company’s stock after selling 60,709 shares during the quarter. SG Americas Securities LLC owned about 0.07% of Amphastar Pharmaceuticals worth $643,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AMPH. Clark Capital Management Group Inc. purchased a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $7,560,000. Denali Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 56.9% in the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after purchasing an additional 76,765 shares during the last quarter. Algert Global LLC grew its holdings in shares of Amphastar Pharmaceuticals by 216.1% during the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock worth $10,471,000 after purchasing an additional 268,612 shares during the period. Bridge City Capital LLC raised its stake in shares of Amphastar Pharmaceuticals by 72.8% in the 4th quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock valued at $6,306,000 after acquiring an additional 99,227 shares during the period. Finally, TD Asset Management Inc raised its holdings in shares of Amphastar Pharmaceuticals by 1.6% during the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after buying an additional 31,160 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Up 2.5%

Shares of NASDAQ AMPH traded up $0.48 during mid-day trading on Tuesday, reaching $20.09. 15,465 shares of the company’s stock were exchanged, compared to its average volume of 543,650. Amphastar Pharmaceuticals, Inc. has a twelve month low of $16.65 and a twelve month high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The business has a fifty day simple moving average of $19.67 and a 200 day simple moving average of $22.60. The firm has a market capitalization of $885.99 million, a price-to-earnings ratio of 12.10, a PEG ratio of 3.86 and a beta of 0.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The business had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. As a group, equities analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMPH. Barclays dropped their target price on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, June 3rd. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, June 22nd. Finally, Weiss Ratings downgraded Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Five investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $22.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.